TEE
AKCA

Tibra Equities Europe’s Akcea Therapeutics Inc AKCA Stock Holding History

Tibra Equities Europe’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-40,800
Closed -$1.16M – 508
2019
Q1 		$1.16M Buy
+40,800
New +$1.19M 0.12% 156

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Tibra Equities Europe's AKCA Position: Q2 2019 in Review

Tibra Equities Europe sold out of Akcea Therapeutics Inc (AKCA) in Q2 2019, closing a stake of 40,800 shares — an estimated $1.16M sold.

Tibra Equities Europe first reported a position in AKCA in Q1 2019 and held it in 1 quarter. The position peaked at $1.16M in Q1 2019. 68 funds tracked by Wall St. Rank hold AKCA as of Q2 2019.

  • Tibra Equities Europe reported no remaining Akcea Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 40,800 Akcea Therapeutics Inc shares in Q2 2019, an estimated $1.16M.
  • Tibra Equities Europe first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Akcea Therapeutics Inc position peaked at $1.16M in Q1 2019.
  • 68 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.